Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0151814 (coronary occlusion)
 3,687 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In the last few years, coronary angioplasty has been the object of real progress in the treatment of total chronic coronary occlusion; The primary success rate of the procedure regularly exceeds 70% with the use of improved equipment; however, these procedures are not without risk with a reported complication rate close to that of angioplasty of non-occlusive stenosis. The use of stents has significantly reduced the restenosis rate, mainly by decreasing the risk of reocclusion. The indications of angioplasty for chronic occlusion remain controversial: the procedure is justified in patients with angina; in asymptomatic patients, angioplasty may improve global and regional left ventricular function in those with documented myocardial viability and limit ventricular remodelling but the results of a randomised trial of systematic angioplasty versus medical treatment in this type of indication are not yet available.
Arch Mal Coeur Vaiss 1999 Nov
PMID:[Angioplasty in chronic coronary occlusion]. 1059 48

The development of a collateral coronary circulation has been well studied by angiography in two main clinical situations: myocardial infarction (by durable coronary occlusion) and angina (due to significant coronary artery stenosis), but only rarely in spastic angina. The authors report the case of severe spasm at the site of non-significant stenosis after a methylergometrine test, with immediate contro-lateral collateral circulation in a patient with a short history of spastic angina without myocardial infarction. This observation demonstrates that collateral circulation may develop very rapidly in spastic angina (without basal ischaemia in the absence of significant coronary stenosis), because this patient only had seven ten-minute episodes of clinical ischaemia. As collateral circulation may mask clinical and electrical signs in spastic angina, this case suggests that angiographic control should be systematic during the methylergometrine test.
Arch Mal Coeur Vaiss 1999 Dec
PMID:[Immediate collateral coronary circulation after a methylergometrin test]. 1066 33

Thrombosis and ischaemia are often linked to an atherosclerotic arterial lesion. An inflammatory process implicating leucocytes and inflammation mediators (cytokines) as well as atheroma plaque rupture liberating tissue factor are at the origin of this pathology. Equally, blood platelets play an important role, not only with the formation of platelet aggregates, but also by their procoagulant action resulting from the exposure of membrane phospholipids. Apoptotic cells release procoagulant microparticles from the plaque, favouring thrombogenesis. In this context reperfusion would a priori restore blood flow, but it is also the origin of cytotoxicity due to the sudden release of necrotising factors. Various animal models are used to experimentally reproduce arterial thrombosis either following or not following ischaemia/reperfusion. Among them the model of progressive coronary occlusion by intraluminal electrical stimulation, the model of quasi-instantaneous thrombosis by the introduction of a copper coil, and the model of ischaemia/reperfusion by occlusion of the left descending coronary for 90 minutes followed by reperfusion have been studied more precisely in the dog. In the rat, cerebral ischaemia followed by reperfusion has been provoked with occlusion of the middle cerebral artery. The studies in dogs show that Enoxaparine significantly reduces the formation of coronary thrombus induced progressively by an anodal current and potentiates the action of the tissular activator plasminogen (t-PA) on a recently formed thrombus. At the level of myocardial ischaemia. Enoxaparine reduces the extent of infarction as well as the neutrophil and platelet accumulation in the infarcted zone or in at risk zone. This effect seems to correlate with an anti-inflammatory type action demonstrated elsewhere in vitro with platelet/neutrophil adhesion in the presence of P-Selectin. In all of these studies standard heparin used under the same conditions proves to be inactive. In the ischaemia/reperfusion model in the dog, aspirin has been shown to be ineffective up to a dose of 6 mg/Kg. Enoxaparine is an example of a possible double anti-thrombotic and anti-ischaemic component in the prevention of disorders caused by the thrombosis-ischaemia-reperfusion triad.
Arch Mal Coeur Vaiss 2002 Nov
PMID:[Thrombosis and ischemia: experimental data]. 1250 Jun 2

The measurement of coronary reserve flow by transthoracic echocardiography of the left anterior descending and the posterior interventricular artery is a new non-invasive reproducible and attractive method which can be performed at the bedside with the proviso of a specific learning curve. The potential value is great: detection of significant (> 70%) coronary stenosis, coronary occlusion, post-angioplasty follow-up, evaluation of intermediate stenoses, coupling with stress echo, reperfusion studies, no reflow detection, post-infarction viability, coronary bypass patency and studies of microcirculation.
Arch Mal Coeur Vaiss 2005 Jun
PMID:[Value of coronary reserve flow measurement by transthoracic echocardiography]. 1600 30

Patients currently treated for acute myocardial infarction receive reperfusion therapy as their only anti-infarct intervention. Although pharmacologic agents have been evaluated in the past for their ability to salvage ischemic myocardium when administered at reperfusion, until very recently none has demonstrated clear efficacy in clinical trials. However, a new generation of interventions has emerged which protects the heart by activating the reperfusion-induced salvage kinase (RISK) pathway. Unlike the disappointing results documented with previously touted putative cardioprotective agents, the preclinical experience with these newer interventions is very consistent indicating that there is a high likelihood that they will be effective clinically. Ischemic postconditioning, which also acts by activating the RISK pathway, has shown marked reduction in infarct size in small-scale trials. Finally, if a strategy for rapidly cooling the heart can be devised so that the in-hospital normothermic ischemic time can be significantly reduced, then infarct size can be even further decreased. In our opinion it is well within our reach using existing technologies to see the day when infarction can be virtually eliminated in the patient with acute coronary occlusion.
Arch Mal Coeur Vaiss 2007 Sep
PMID:Protecting the acutely ischemic myocardium beyond reperfusion therapies: are we any closer to realizing the dream of infarct size elimination? 1803 9

Percutaneous implantation of a bioprosthesis for the treatment of degenerative aortic stenosis ushered in a new era for interventional cardiology, and now represents the best therapeutic option for a growing number of patients for whom surgical aortic replacement would be too risky. This is the case in about a third of symptomatic patients affected. Between 2003 and 2005, we performed initial feasibility studies (I-REVIVE and RECAST) in Rouen, on non-operable patients in a critical state, included for purely compassionate reasons. The valve used was a pericardial bioprosthesis mounted in an expandable balloon stent. The mean age of the patients was 80 years, all had multiple co-morbidity and had been turned down by the cardiac surgeons. In 33 of the 36 included patients, the technique was attempted by the anterograde trans-septal approach (n=27, success rate 80%) or by the retrograde arterial route (n=7, success rate 57%). Echocardiography following implantation revealed a final aortic surface area of 1.70 cm2 and a transvalvular gradient of 9 mmHg. A significant paravalvular aortic leak was noted in 5 cases. There were 6 deaths by 1 month, related to the procedure, and 10 deaths by 6 months, from non-cardiac causes and not related to the procedure. There was no occurrence of coronary occlusion, secondary displacement or dysfunction of the prosthesis. In December 2006, 8 patients reached 2 years of follow up, and two others reached 3 years, symptom free and still with an unchanged valvular function. Significant technological improvements have made the technique simpler, quicker and safer, with very much improved short and long term results. The new trans-apical approach is under evaluation with some promising initial results. More than 280 patients have been implanted to date. Other implantable prostheses are under evaluation. This therapeutic modality looks likely to develop rapidly, and in the near future it should offer a new and optimal solution for all high surgical risk or non-operable patients.
Arch Mal Coeur Vaiss 2007 Nov
PMID:[Aortic bioprosthesis implanted percutaneously: three year follow up]. 1820 90


<< Previous 1 2 3 4